Pipobroman therapy of XXXX vera.

@entity1 @entity6582 @entity417 @entity882 @entity44615 @entity11140 @entity3052 @entity1431 @entity1583 @entity1863 @entity3151
Between 1971 and 1981, 74 @entity1 with @entity6582 vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen. Complete remission was achieved in 51 of 54 previously untreated @entity1 (94.4%) and in 17 of 20 @entity1 (85%) previously treated wih radioactive @entity3151 (32 p) and @entity1863 . The earliest modifications were noted on day 16, and on the average, blood counts were normal by day 45. Thirty percent of the @entity1 relapsed, the mean duration of the remission being 17.5 mo. Following recurrence pipobroman was consistently effective in the same doses but the mean duration of the next remissions was 10 mo. Transient @entity1431 and @entity882 occurred in 8% and 7% of @entity1 , respectively, during initial phase, and @entity417 was noted in 3 @entity1 . @entity11140 was noted in 20% of @entity1 during maintenance phase. Three cases of @entity3052 and 3 cases of osteomyelosclerosis were recorded, all occurring in @entity1 who had previously received 32 p and/or @entity1863 . No @entity1583 were seen among @entity1 treated with @entity44615 alone; follow-up exceeded 6 yr for 20 @entity1 and the median follow-up period was 3.6 yr. Pipobroman appears safer than other alkylating agents; it is as effective as 32 p and works more quickly. Longer follow-up will be required to evaluate the drug's oncogenic potential, which is still not known.
